Drug Database
FI

filgrastim (long-acting)

✓ Approved

Win Medica · CSF3R · Recombinant Proteins

What is filgrastim (long-acting)?

filgrastim (long-acting) is a recombinant proteins developed by Win Medica. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyWin Medica
Drug ClassRecombinant Proteins
Molecular TargetCSF3R
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Win Medica

Mechanism of Action

Molecular Targets

filgrastim (long-acting) acts on 1 molecular target:

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

filgrastim (long-acting) is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersBone marrow disorder✓ Approved

Related Research Articles

PubMedArthroscopy techniques2026-07-25

Arthroscopic Rotator Cuff Repair With Autologous Biologic Augmentation Using Biceps Tendon Redirection and Incorporation.

Ben-Ari Erel E, Ramires Luciano L, Gilmer Brian B BB, Marvil Sean C SC et al.

The long head of the biceps tendon is a valuable autologous tissue for biologic augmentation in rotator cuff repair. Redirecting the long head of the biceps tendon can enhance its role as a humeral head depressor, limiting superior humeral head migration, and improving rotator cuff force couple and shoulder biomechanics. Incorporating the long head of the biceps tendon into the rotator cuff repair construct can enhance the repair by acting as a biologic internal brace, promoting load sharing and improving structural integrity. This technique may improve healing, repair durability, and functional outcomes, especially in large or revision tears with poor tissue quality.

PMID 42499859
Read full article →
PubMedJournal of the American Pharmacists Association : JAPhA2026-07-25

Community pharmacists' perceptions of long-acting injectable buprenorphine administration in community pharmacies: A cross-sectional survey study.

Marley Grace G, Farrel Brianna B, Carpenter Delesha D

Long-acting injectable buprenorphine (LAI-B) is an evidence-based medication for opioid use disorder (MOUD), but its implementation in community pharmacies has not been well studied. This study's objective was to assess southeastern North Carolina (NC) community pharmacist perspectives on the perceived acceptability, appropriateness, and feasibility of LAI-B administration and identify the barriers and facilitators to LAI-B administration in community pharmacies. We conducted an online survey of practicing community pharmacists between January 14 and March 14, 2026. The survey assessed knowledge of and willingness to administer LAI-B, perceived benefits and barriers, training needs, and perceived acceptability, appropriateness, and feasibility of administering LAI-B. Descriptive statistics are reported. Forty-four eligible responses were included in the analysis (response rate= 16%). On average, pharmacists were neutral to somewhat willing to administer LAI-B and also had neutral-to-positive perceptions of acceptability, appropriateness, and feasibility. The most frequently endorsed benefits of LAI-B were decreased diversion, supporting patients in recovery, reducing overdose deaths, and increasing revenue. The most prominent barriers involved reimbursement and payment. Other barriers included limited training, workflow constraints, and lack of provider referrals. Pharmacists reported low knowledge regarding LAI-B Risk Evaluation and Mitigation Strategy requirements, follow-up monitoring, and storage, and expressed interest in training on those topics. Pharmacy-based LAI-B administration could be a promising strategy to expand access to MOUD. However, implementation will require clearer reimbursement pathways, targeted training, and workflow support.

PMID 42498130
Read full article →
PubMedActa naturae2026-07-25

Long Non-Coding RNAs: Allies and Enemies of HIV Infection.

Kikhai T F TF, Mashkovskaia A V AV, Oretskaya T S TS, Agapkina Y Y YY et al.

significant impact on the pathogenesis of viral infections by acting as both positive and negative regulators of viral gene expression. This review summarizes the available data on lncRNAs associated with human immunodeficiency virus type 1 (HIV-1). LncRNAs can regulate both the active replication cycle and the latent phase of the HIV-1 infection, during which the integrated proviral DNA remains transcriptionally silent. Moreover, lncRNAs may serve as diagnostic markers and are potential therapeutic targets. A deeper understanding of the intricate interactions between lncRNAs and HIV-1 is essential for developing innovative treatments for the HIV infection and the associated acquired immunodeficiency syndrome (AIDS).

PMID 42499673
Read full article →
PubMedImmunotherapy advances2026-07-25

Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer.

Parent Brendan D BD, Kelly Anthony E AE, Hoffman Megan T MT, Dougan Michael M et al.

Growth factors, including granulocyte colony-stimulating factor (G-CSF; pegfilgrastim, filgrastim), are used for prophylaxis or treatment of chemotherapy-induced neutropenia, yet their effects on antitumour immunity remain incompletely understood. We previously found that serum from patients with pancreatic ductal adenocarcinoma (PDAC) treated with multiagent chemotherapy plus G-CSF drove differentiation of T cell-suppressive monocytes in vitro, suggesting that supportive care interventions may shape immune responses in this disease. We evaluated the immunologic and therapeutic impact of G-CSF in two murine PDAC models that differ in their baseline frequencies of infiltrating T cells and in their responsiveness to checkpoint blockade immunotherapy. In poorly immunogenic, T-cell-low tumours, use of G-CSF did not affect tumour growth or response to chemo- or immunotherapy, although neutrophil recovery was improved in mice receiving FOLFIRINOX and G-CSF compared to chemotherapy alone. In immunogenic tumours with a robust endogenous T-cell response, combination anti-PD1 and anti-CTLA-4 therapy resulted in durable tumour clearance. Combination with G-CSF diminished the effectiveness of checkpoint blockade and resulted in significantly fewer cured mice. G-CSF, commonly used for supportive care with FOLFIRINOX and other chemotherapy regimens, induces systemic immune suppression that can reduce the efficacy of T-cell-targeting immunotherapies.

PMID 42500327
Read full article →
PubMedCell2026-07-25

Dynamic dimer-of-dimers architecture defines Mg2+ transport in human CNNM4.

Bai Zhiyong Z, Zhou X Edward XE, Lü Wei W, Du Juan J

Mg2+ is essential for all living organisms, yet its transport across mammalian membranes remains poorly understood. Here, we present cryoelectron microscopy (cryo-EM) structures of a full-length mammalian Mg2+ transporter on the plasma membrane, human CNNM4, in outward-facing and occluded states, revealing an unexpected tetrameric assembly organized as a dimer of asymmetric dimers-distinct from the symmetric dimers in prokaryotic homologs and long assumed for eukaryotic CNNMs. We show that Mg2+/ATP binding stabilizes the dynamic intracellular domains and promotes tetramerization, while an acidic patch binds additional Mg2+, potentially acting as a sensor to couple cytoplasmic Mg2+ levels to transport activity. Within the transmembrane domain, a key glutamate flips upon Na+ binding and destabilizes the Mg2+-binding site in the outward-facing state, thereby promoting Mg2+/Na+ exchange. Together, these findings establish a mechanistic framework for CNNM transport and regulation that diverges from prokaryotic models and links CNNM function to human physiology and disease.

PMID 42497866
Read full article →
PubMedJAC-antimicrobial resistance2026-07-25

Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring.

Giuliano Simone S, Martini Luca L, Merelli Maria M, Turicchi Giulia G et al.

Oritavancin is a long-acting semisynthetic lipoglycopeptide with potent activity against a broad range of Gram-positive pathogens. Its multimodal mechanism of action and prolonged terminal half-life allow for extended dosing intervals, making it an off-label option for invasive infections requiring long-term antimicrobial exposure. However, evidence supporting its use in infective endocarditis and cardiac device-related infections remain limited. We performed a retrospective multicentre observational study including adult patients treated with multidose oritavancin for infective endocarditis and cardiac device-related infections between 2020 and 2025. Oritavancin was administered as consolidation or as long-term suppressive therapy. Demographic, clinical, microbiological, pharmacological, and outcome data were collected. Therapeutic drug monitoring was performed, and pre-dose plasma concentrations were analysed. Clinical outcomes included clinical cure, microbiological failure, adverse events, and 30- and 90-day all-cause mortality. Nine patients were included. Oritavancin was mainly administered at 1200 mg per dose, with a median dosing interval of 10 days. Clinical success was achieved in 6/9 patients (66.7%). One patient discontinued therapy due to infusion-related adverse events, and two experienced microbiological failure, both in left ventricular assist device-related infections. No 30- or 90-day mortality was observed. TDM, when performed, demonstrated persistent pre-dose plasma concentrations over several weeks, with marked interindividual variability across patients and intra-individual temporal changes over time, including drug accumulation in some cases. Multidose oritavancin appears to be a promising consolidation or suppressive strategy in selected patients with complex Gram-positive endovascular infections. Prospective studies are needed to define optimal dosing regimens and the role of TDM in this setting.

PMID 42500354
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about filgrastim (long-acting)